Peptide-Targeted Radiation Therapy Achieved Sustained Improvement in a Metastatic Pituitary Tumor After a Decade of Failed Treatments | Research

The takeaway

A patient with metastatic ACTH-secreting pituitary tumor who failed multiple treatments over a decade finally achieved sustained clinical, biochemical, and structural improvement with peptide receptor radionuclide therapy (177Lu-DOTATATE).

>10 years of failed treatments reversed
Only peptide receptor radionuclide therapy (177Lu-DOTATATE) achieved sustained clinical, biochemical, and structural improvement after a decade of surgeries, radiation, and drug therapy

What the researchers found

A 55-year-old male with an ACTH-secreting pituitary neuroendocrine tumor (PitNET) underwent over a decade of treatments:

- Recurrent transsphenoidal resections (multiple surgeries)

- Gamma knife irradiation

- Somatostatin analog therapy

- Steroidogenesis inhibitors

None achieved lasting control. Metastatic bone deposits were eventually discovered. Only after initiating 177Lu-DOTATATE PRRT did the patient achieve sustained clinical improvement (symptoms), biochemical improvement (hormone levels), and structural improvement (tumor shrinkage).

The authors note that the limited published cases of PRRT in metastatic PitNET show mostly favorable outcomes: tumor stability and/or shrinkage with limited adverse events (primarily mild blood count reductions).

Why it matters

Metastatic pituitary tumors are among the most challenging cancers to treat, with no standard therapy and limited options after surgery and radiation fail. This case demonstrates that PRRT — which uses a peptide to deliver targeted radiation directly to tumor cells expressing somatostatin receptors — can succeed where everything else has failed. As PRRT becomes more widely available (it's FDA-approved for other neuroendocrine tumors), this evidence supports expanding its use to aggressive pituitary tumors.

How the study worked

This is a single-patient case report describing the clinical course of a 55-year-old male with metastatic ACTH-secreting PitNET. The report chronicles his treatment history, the detection of metastatic disease, and the response to 177Lu-DOTATATE PRRT. The authors also review the limited published literature on PRRT use in metastatic PitNET.

What this study cannot tell us

This is a single case report — the lowest level of clinical evidence. Individual patient responses cannot be generalized to all patients with metastatic PitNET. The patient's specific tumor biology (receptor expression, prior treatments) may have uniquely favored PRRT response. Long-term outcomes and potential late adverse effects are not fully described. Selection bias exists in published case reports, which tend to report favorable outcomes. No comparison group exists to determine whether improvement was due to PRRT or other factors.

How to read the evidence

This is a single case report, which provides the lowest level of clinical evidence. While compelling for this individual patient, case reports cannot establish efficacy or safety for a broader population. However, it adds to a growing collection of favorable PRRT cases in metastatic PitNET that collectively support further study.

When this study was published

Published in 2025, this case report reflects the current expanding use of PRRT beyond its original FDA-approved indication for gastroenteropancreatic neuroendocrine tumors.

The bigger picture

177Lu-DOTATATE (Lutathera) was FDA-approved in 2018 for gastroenteropancreatic neuroendocrine tumors and has transformed outcomes for those patients. Its use in pituitary tumors is off-label but biologically logical — many pituitary tumors express somatostatin receptors that the DOTATATE peptide targets. This case adds to the growing evidence that PRRT's benefits extend to neuroendocrine tumors beyond its original approved indication, potentially establishing a new treatment paradigm for aggressive pituitary cancers.

Questions still open

Should 177Lu-DOTATATE PRRT be introduced earlier in the treatment sequence for aggressive pituitary tumors, rather than as a last resort?
What somatostatin receptor expression level is needed on pituitary tumors to predict PRRT response?
Could combining PRRT with immunotherapy or targeted therapies improve outcomes further in metastatic pituitary tumors?

Common questions

How does peptide receptor radionuclide therapy (PRRT) work?

PRRT uses a peptide (DOTATATE) that specifically binds to somatostatin receptors, which are found in high numbers on many neuroendocrine tumor cells. The peptide is attached to a radioactive atom (lutetium-177), so when the peptide-radiation combination is injected into the bloodstream and binds to tumor cells, it delivers targeted radiation directly to the tumor from the inside — like a guided missile. This allows high-dose radiation to reach tumor cells throughout the body while sparing most normal tissue.

Why did this patient need so many treatments before PRRT worked?

Metastatic pituitary tumors are exceptionally rare and aggressive. Standard treatments — surgery, radiation, and hormone-blocking drugs — are designed for tumors confined to the pituitary gland. Once the tumor spread to the bones, these local treatments couldn't reach all disease sites. PRRT was effective because it's a systemic treatment — the radioactive peptide travels through the blood and targets tumor cells wherever they are in the body, including metastatic deposits that surgery and focused radiation can't reach.

Read the original research

Success of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor.

Endocrine oncology (Bristol, England), 5(1), e250073

View on PubMed ↗Publisher’s paper ↗

Citation

Wolf, Katherine I; Lu, Zhonglin; Hesseltine, Elizabeth A; Wong, Ka-Kit; Worden, Francis P; Else, Tobias. (2025). Success of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor.. Endocrine oncology (Bristol, England), 5(1), e250073. https://doi.org/10.1530/EO-25-0073